Objective To study the clinical effect of desitabine combined with CAG in the treatment of recurrent refractory acute myeloid leukemia. Methods Randomly selected our hospital 90 cases of recurrence of refractory acute myeloid leukemia patients(all are in June 2017 to June2018), according to the grouping of lottery patients, on average, will be divided into two groups, control group use the CAG solution treatment, the observation group treated with combination of his west marina, to evaluate curative effect of the two groups, and to observe adverse reactions occur, the two groups after treatment at the end of the treatment after a year of follow-up, in patients with records of two groups of live and death.Results After different treatment regimens, the combined treatment effect of the two groups was superior to that of the control group(95.56%>75.56%), In addition, the number of adverse reactions in the observation group was less than that in the control group(8.89%<26.67%), and the difference between the two groups was statistically significant(P<0.05). Moreover, one year after the end of treatment, the survival rate of the observation group was higher than that of the control group, and the mortality rate was lower than that of the control group. The difference between the two groups was statistically significant(P<0.05). Conclusion In the treatment of patients with recurrent refractory acute myeloid leukemia, the application of dioxetabine combined with CAG scheme can effectively improve the efficacy and safety of patients, so it is worthy of more promotion.